Skip to content
Investing in women’s health is a gold mine that few healthcare investors have yet to tap, according to a new study that has come […]
BIO 2024: Investing in women’s health is an untapped gold mine Read More »
In August 2020, the World Health Organization (WHO) adopted a global strategy to eliminate cervical cancer in our lifetime. “To eliminate cervical cancer,” according
We can eliminate cervical cancer in our lifetime – here’s how Read More »
On June 7, the U.S. Food and Drug Administration (FDA) approved an expanded age indication for GSK’s Arexvy, making it the first respiratory syncytial
FDA approves Arexvy for patients 50–59 Read More »
With the passage of the Inflation Reduction Act (IRA) and the growing number of prescription drug affordability boards (PDABs), patients and the biotech industry
BIO 2024: PDABs and IRA pose a murky threat to patient access Read More »
Getting government support for a biotech startup no longer need be a slow and painful process, according to staff and fundees of the Advanced
ARPA-H offers fast, flexible support to biotech startups, panelists tell BIO 2024 Read More »
Biopharma supply chains, streamlining regulation, and other critical issues came up when the leader of the U.S. agency regulating drugs spoke with the leader
FDA’s Dr. Califf talks supply chains, clinical trial diversity, and America’s health Read More »
Founded 44 years ago, Amgen was “created at the dawn of the biotechnology revolution,” said Robert A. Bradway, CEO of Amgen, “when faculty at
“Biotechnology, that’s a great, big word that just means hope.” That’s what Christopher Reeve said years ago at a BIO International Convention. Little did
Admiral William H. McRaven and BIO CEO John F. Crowley talk hope in biotech Read More »
Viola Davis is a world-renowned actress, writer, and producer, holding the coveted EGOT status in Hollywood (winning an Emmy, Grammy, Oscar, and two Tony
BIO 2024: Viola Davis and Aaron Lazar share lessons on life and legacy Read More »
The pollster pulled no punches: The biopharma industry has a poor public image, and politicians in both parties are ready to back drug price
Biotech needs to polish its message as elections approach, experts say Read More »
